86
Participants
Start Date
December 22, 2021
Primary Completion Date
July 26, 2023
Study Completion Date
July 26, 2023
Envofolimab
300mg,Q3W (arm A,B and C)or 200mg, Q2W(arm D)
BD0801
2mg/kg,Q3W(armA, B and C) or 2mg/kg,Q2W
Docetaxel
75mg/m2,Q3W
Irinotecan
180 mg/m2,Q2W
Leucovorin calcium
400mg/m2,Q2W
5-Fluorouridine
2400 mg/m2,Q2W
Beijing Cancer Hospital, Beijing
The First Affiliated Hospital of Bengbu Medical College, Bengbu
Jilin Cancer Hospital, Changchun
Hunan Cancer Hospital, Changsha
Sichuan Cancer Hospital, Chengdu
Dezhou People'S Hospital, Dezhou
First Affiliated Hospital of Gannan Medical Universit, Ganzhou
Nanfang Hospital of Southern Medical University, Guangzhou
Sun Yat-sen University affiliated with the Sixth Hospital, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
Shaw Hospital Affiliated to Medical College of Zhejiang Universit, Hangzhou
Zhejiang Provincial People'S Hospital, Hangzhou
Harbin Medical University Cancer Hospital, Harbin
Anhui Chest Hospital, Hefei
Anhui Provincial Cancer Hospital, Hefei
The First Affliated Hospital Of Anhui Medical University, Hefei
Shandong Cancer Hospital, Jinan
Mianyang Central Hospital, Mianyang
Liaoning Cancer Hospital, Shenyang
The Fourth Hospital of Hebei Medical University, Shijia Zhuang
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Yantai Yuhuagnding Hospital, Yantai
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
INDUSTRY